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The primary aim of this study was to determine antimicrobial resistance in coagulase negative staphylococci (CoNS) from healthy 16 
adults in the community. Healthy adults (n=114) were swabbed on six body sites; both armpits, both knee pits and both sides of the 17 
groin. Species determination was performed using MALDI-TOF and susceptibility testing for eleven relevant antimicrobials was 18 
performed by the disc diffusion method and minimal inhibitory concentration gradient test. 19 
In total, 693 CoNS-isolates were identified. Susceptibility testing was done on 386 isolates; one CoNS from each species found on 20 
each participant from the different body sites. The prevalence of antimicrobial resistance in the CoNS isolates were; erythromycin 21 
(24.6%), fusidic acid (19.9%), tetracycline (11.4%),clindamycin (7.8%), gentamicin (6.2%) and cefoxitin (4.1%). Multidrug resistance 22 
was observed in 5.7% of the isolates. Staphylococcus epidermidis and S. hominis were the first and second most prevalent species on 23 
all three body sites. We conclude that CoNS isolates from healthy adults in the community have a much lower prevalence of 24 
antimicrobial resistance than reported in nosocomial CoNS isolates. Still, we believe that levels of resistance in community CoNS 25 
should be monitored as the consumption of antimicrobials in primary care in Norway is increasing.  26 
 27 
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The development and global spread of antimicrobial resistance is a threat to modern medicine. The commensal skin flora, dominated 33 
by coagulase negative staphylococci (CoNS), may act as a reservoir of antimicrobial resistance, and transfer resistance genes to more 34 
virulent staphylococci such as Staphylococcus aureus (1-4). Over the last decades, CoNS have received increased interest as important 35 
opportunistic nosocomial pathogens frequently involved in medical implant infections and infections in immunocompromised patients, 36 
e.g. patients with haematological diseases and very preterm infants (5). Studies on antimicrobial resistance in CoNS have mainly 37 
focused on invasive isolates, commonly from hospitalized patients (6-8). Multidrug-resistant hospital adapted clones have been 38 
identified in both S. epidermidis and S. haemolyticus (6, 9). However, only limited data exist regarding antimicrobial resistance among 39 
community CoNS isolates (10-12). Furthermore, CoNS species with different resistance and virulence traits may have different niches 40 
on the human body (2).  41 
 42 
The primary aim of this study was to determine susceptibility to commonly used antimicrobial agents in a selection of CoNS isolates 43 
from healthy adults in the community. Secondly, we report the body site distribution of CoNS on three body sites screened in this 44 






MATERIAL AND METHODS 49 
Healthy adult volunteers (age 18-49 years, mean age; 25.5 years) were recruited, primarily from different sport teams (basketball, n= 50 
14, ice hockey, n= 9, four different football teams n=55 and members of a student’s sports centre n=19) and office employees (n= 17). 51 
All participants filled in a questionnaire regarding antimicrobial consumption, hospitalization and travel abroad during the last three 52 
months. Health care workers and volunteers who reported antimicrobial consumption and/or contact with health care institutions 53 
during the last three months were not included in the study.  54 
 55 
All participants were swabbed with Amies charcoal transport swabs (Sarstedt, Nümbrecht, Germany) on six body sites; both armpits, 56 
both knee pits and both sides of the groin. Swabs were streaked on blood agar plates (Oxoid, Basingstoke, England) and incubated 57 
overnight (16-20 hours) at 37°C. All visible CoNS with different morphotypes on blood agar plates were selected for further analyses 58 
(5-36 colonies from each participant). The phenotypes were characterized by colonies of different diameter with white, grey, creamy or 59 
yellow pigmentation and moderately heavy, weak or absent haemolysis.  60 
 61 
Species determination was performed with MALDI-TOF MS using a Microflex LT instrument (Bruker Daltonics, Massachusetts, 62 
USA), Flexcontrol software and the Biotyper database (Bruker Daltonics, Massachusetts, USA) (13). A simple extraction method with 63 
70 % formic acid (Sigma-Aldrich, St. Louis, MO, USA) was used on the isolates before adding HCCA matrix solution (Bruker 64 
Daltonics, Massachusetts, USA / Sigma-Aldrich, St. Louis, MO, USA). Both positive (ATCC 9144 S. aureus) and negative (matrix 65 
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solution) controls were applied on each test plate run on the MALDI-TOF MS. All samples were run in parallel. Processing of samples 66 
were done according to the user manual (13) Only samples that obtained a log (score) value of ≥ 2 were used further, as these results 67 
are considered to give a high probability of identification at the species level (14).  68 
After species determination, one CoNS-isolate of each species was randomly selected from each participant, and underwent testing for 69 
antimicrobial susceptibility. Antimicrobial susceptibility testing and interpretation was performed according to EUCAST guidelines 70 
(15). Oxoid MH agar plates were used (Oxoid, Basingstoke, England).The disk diffusion test was used for cefoxitin (as a marker for 71 
methicillin resistance), trimethoprim-sulfamethoxazole (TMS), clindamycin, erythromycin, fusidic acid, gentamicin, linezolid, 72 
tetracycline, ciprofloxacin and rifampicin (Oxoid, Basingstoke, England). A minimal inhibitory concentration (MIC) gradient test was 73 
used for vancomycin susceptibility testing of all isolates, and for selected isolates with linezolid inhibition zones around defined 74 
breakpoints. (Liofilchem, Roseto degli Abruzzi, Italy). ATCC 29213 S. aureus was used as reference strain. All isolates were also 75 
tested for inducible resistance to clindamycin (15). Multidrug resistance (MDR) was defined as resistance to at least three classes of 76 
antimicrobial agents.  77 
 78 
Ethical approval 79 
The Regional Committee (REC) for Medical Research Ethics approved the collection of CoNS isolates (REC number 2013/974/REK). 80 





In total, 114 participants (57 male and 57 female) were included in the study. None of the participants had consumed any antimicrobial 84 
agents, worked at, or been admitted to a health care institution 3 months prior to the swabbing. A total of 693 CoNS were identified 85 
from the different body sites of the 114 volunteers (Figure 1). Eleven potential Staphylococcus species were not included because of a 86 
log (score) value < 2 on MALDI-TOF MS. S. epidermidis and S. hominis were the first and second most prevalent species at all three 87 
body sites, body site distribution and prevalence is listed in Figure 1. 88 
 89 
We performed antimicrobial susceptibility testing on 386 isolates; one CoNS from each species found on each participant (Table 1). 90 
Different CoNS species per person included in the antimicrobial susceptibility testing varied from one to seven (mean=3). In total 110 91 
S. epidermidis, 93 S. hominis, 59 S. capitis, 48 S. haemolyticus, 38 S. lugdunensis, 13 S. saprophyticus, and 25 other CoNS were tested. 92 
The highest prevalence of resistance was towards erythromycin 95/386 (24.6 %), fusidic acid 77/386 (19.9 %) and tetracycline 44/386 93 
(11.4 %). There was a very low prevalence (< 2%) of resistance towards rifampicin, ciprofloxacin and TMS. Overall, 16/386 (4.1 %) 94 
of CoNS isolates were methicillin resistant. Resistance to vancomycin or linezolid was not detected in any isolates. MDR was 95 
observed in 5.2% of the isolates. S. hominis displayed the highest prevalence of MDR (10.8%), followed by S. epidermidis (6.4%) and 96 
S. haemolyticus (6.3%). In 16.6% of the participants, all of the tested strains were susceptible to all antimicrobial agents. In 13.5 % of 97 
the participants, all strains tested displayed resistance to one or more antimicrobial agents. Resistant isolates were not associated with 98 




There was no correlation between the prevalence of antimicrobial resistance and participants belonging to different sports teams, nor 101 
was there any differences observed in prevalence of antimicrobial resistance in the different age groups or between the male and 102 




This is, to our knowledge, the largest, recent study focussing on antimicrobial susceptibility in community CoNS. The commensal 107 
CoNS isolates displayed resistance to all antimicrobial classes tested apart from vancomycin and linezolid. MDR was detected in 5.2% 108 
of the isolates. However, in around 1 of 6 participants no antimicrobial resistant CoNS-isolates were found. The highest prevalence of 109 
antimicrobial resistance was towards erythromycin, fusidic acid, tetracycline and clindamycin, all antimicrobial agents commonly 110 
prescribed in primary health care to treat respiratory tract and skin infections (16). A recent Portuguese study on community CoNS 111 
reported overall higher prevalence of resistance than in our Norwegian isolates, and showed a higher prevalence of resistance towards 112 
agents commonly prescribed antibiotics in primary care (12). Similar rates of antibiotic resistance have also been reported in 113 
community isolates of S. epidermidis, (11, 17, 7, 18). It has previously been demonstrated that CoNS skin commensals easily develop 114 
resistance towards ciprofloxacin and betalactams, due to secretion of these antimicrobial agents in sweat, reflecting the ability to 115 
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rapidly adapt to changing external pressure (19, 20). However, the rates of resistance to cefoxitin and ciprofoxacin was low in our 116 
study.  117 
 118 
In Norway, around 85% of the total human consumption of antimicrobial agents is in the primary care setting. The three most 119 
commonly prescribed groups of antibiotics are penicillins, tetracyclins and macrolides (21, 22), the consumption in Troms county is 120 
marginally lower that at the national level (personal communication, Hege Blix, Norwegian Institute of Public Health). The high 121 
consumption of macrolides in Norway may explain the relatively high prevalence of macrolide resistance among community CoNS 122 
isolates (22). In the Norwegian national guidelines for antibiotic use in primary care, macrolides are not recommended as first-line 123 
therapy for any other conditions than pneumonia caused by mycoplasma and/or chlamydophilia (23), but the relatively high 124 
consumption indicates that guidelines are not universally followed. Overuse of macrolides may contribute to increased antibiotic 125 
resistance (24), and the current macrolide use in Norway is higher than wanted by the regulatory authorities. 126 
 127 
Among hospital CoNS isolates the resistance pattern is markedly different (8, 10, 25). A Norwegian study on antimicrobial resistance 128 
patterns of clinical CoNS isolates from total hip arthroplasty infections during 1993-2007 reported an increase in methicillin resistance 129 
rates from 57 to 84%, as well as increasing rates of resistance to most other antimicrobials tested (26). Antimicrobial resistance is, 130 
however, not routinely monitored in commensal CoNS and we do not know if the prevalence of resistance in the community has 131 
increased. Compared to community isolates, clinical isolates have a much higher prevalence of antimicrobial resistance, most likely 132 
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reflecting that hospital adapted resistant clones seem to outcompete the commensal flora (9). Only 5.2 % of the community CoNS in 133 
our study displayed MDR, but these isolates may also have a competitive advantage if entering the hospital and being exposed to the 134 
increased antimicrobial pressure in the hospital setting. Interestingly we observed that 13.5% of the participants were colonised with 135 
isolates that were resistant to one or more antimicrobial agents. These individuals might act as a reservoir of antimicrobial resistance 136 
genes in the community to other CoNS or S. aureus. Acquisition of antimicrobial resistance genes by horizontal gene transfer between 137 
closely related staphylococcal species has been hypothesised as the main cause for the successful spread of the community associated 138 
USA 300 methicillin-resistant S. aureus clone (27, 28). 139 
 140 
Selection of swab sites for collection of strains was based on previously reported body sites frequently colonised with CoNS; the 141 
axillae, the groin and a the more dry extremities such as the knee (29, 30). As expected, S. epidermidis was the dominant species on all 142 
body sites. The second most common species was S. hominis, previously reported to commonly colonize the axillae, arms and legs and 143 
areas with apocrine glands such as the inguinal and perineal areas (31, 32, 29). Of note is that S. capitis, previously thought to be most 144 
prevalent on the head, was frequently found in the samples from the groin and the knee pit, whereas S. saprophyticus, a urinary tract 145 




This study has strengths and limitations. We took care to ensure that the isolates were truly community isolates by not including 148 
volunteers who recently had been treated with antimicrobial agents or were working in health care facilities. Due to a large number of 149 
isolates we decided to restrict susceptibility testing to one isolate of each species from each participant. Spread of community acquired 150 
methicillin resistant S. aureus between members of sports teams in close contact sports, such as football has been demonstrated (33, 151 
34). As we have swabbed groups of participants belonging to the same sports teams, we might have introduced a potential bias due to a 152 
possible spread of strains between members of the same sports teams, carrying specific antimicrobial resistance genes. This could 153 
artificially increase the prevalence of antimicrobial resistance in our collection, compared to the general population. However, we 154 
believe that the large number of isolates included to a large extent reflect the antimicrobial susceptibility pattern of CoNS outside 155 
hospitals in Norway. Our data on body site distribution clearly show that different CoNS species may have other body niches than 156 
previously reported (29, 30) We did not perform susceptibility testing on all 693 isolates detected from all body sites. Thus, we cannot 157 
specify resistance pattern to each body site. 158 
There is a paucity of information regarding antimicrobial resistance in commensal CoNS. We conclude that the prevalence of 159 
antimicrobial resistance among community CoNS in Norway is relatively low. However, MDR is present and these isolates may be 160 
more adaptable when introduced in a hospital setting. With the increase in antimicrobial prescriptions in primary care in Norway (22), 161 
prevalence of resistance in community CoNS should be monitored. Further comparative studies should be conducted in order to 162 
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Table 1: Prevalence of antimicrobial resistance (%) in 386 community CoNS isolates from healthy adults. 282 
 283 
* MDR: Multi Drug Resistant, resistant to three or more classes of antimicrobial drugs.  284 
** Other CoNS-species S. caprae, S. warneri, S. condimenti, S. equorum, S. pasteuri, S. salivarius, S. simulans, S. pettenkoferi 285 
*** 6 additional isolates (two S. epidermidis, two S. hominis, one S. lugdunensis and one S. pettenkoferi isolate) were omitted from 286 
susceptibility testing due to poor growth. 287 
 
N Cefoxitin TMS Clindamycin Erythromycin Fusidic 
acid 
Gentamicin Tetracycline Ciprofloxacin Rifampicin MDR* 
S. epidermidis 110 2 (1.8) 2 (1.8) 8 (7.3) 29 (26.4 ) 29 (26.4 ) 11 (10.0 ) 6 (5.5) 0 1 (0.9) 5 (4.5) 
S. hominis 93 6 (6.5) 2 (2.2) 11 (11.8) 32 (34.4) 29 (31.2) 7 (7.5) 28 (30.1) 1 (1.1) 0 10 (10.8) 
S. capitis 59 3 (5.1) 0 4 (6.8) 2 (3.4) 6 (10.2) 3 (5.1) 4 (6.8) 2 (3.4) 0 2 (3.4) 
S. haemolyticus 48 3 (6.3) 0 7 (14.6) 29 (60.4) 6 (12.5) 1 (2.1) 4 (8.3) 2 (4.2) 0 3 (6.3) 
S. lugdunensis 38 0 0 0 1 (2.6) 2 (5.3) 0 1 (2.6) 0 0 0 
S.saprophyticus 13 2 (15.4) 0 0 0 5 (38.5) 0 0 0 0 0 
Other CoNS** 25 0 0 0 2 (8) 0 2 (8) 1 (4) 0 0 0 
Total*** 386 16 (4.1) 4 (1.0) 30 (7.8) 95 (24.6) 77 (19.9) 24 (6.2) 44 (11.4) 5 (1.3) 1 (0.3) 20 (5.2) 
